Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.70725 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Xiaoyang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Genital Neoplasms, Female, Leupeptins, Antineoplastic Agents. Die Arbeit nennt 86 Literaturangaben. Gefördert von: the Special Project for Scientific and Technological Innovation Talents under the Xingtai City innovation Capacity Enhancement Plan, the Three-Three-Three Talent Project of Hebei Province.
Abstract (Originalsprache)
The ubiquitin‐proteasome system (UPS) is the primary mechanism for intracellular protein degradation, crucial in oncogenesis and tumor progression. Proteasome inhibitors disrupt UPS‐mediated proteolysis, effectively inhibiting neoplastic cell proliferation, and have become established therapeutic targets in oncology. Gynecologic malignant tumors pose a significant threat to women's reproductive health globally. Among proteasome inhibitors, MG132 has garnered extensive attention in gynecologic oncology due to its multifaceted mechanisms, including cell cycle regulation, NF‐κB signaling inhibition, and modulation of p53 activity. This review consolidates recent research on the therapeutic potential of MG132 in gynecologic malignant tumors, with a focus on its molecular mechanisms of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Gynecology, Xingtai People's Hospital, Xingtai, Hebei, China.
- Department of Obstetrics and Gynecology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China.
ORCID-Profile: Xiaoyang Liu, Zizhang Li
Förderung
- the Special Project for Scientific and Technological Innovation Talents under the Xingtai City innovation Capacity Enhancement Plan
- the Three-Three-Three Talent Project of Hebei Province
Zitieren
APA
Liu, X., Li, Z., Zhang, C., Liang, J., & Zhou, N. (2026). Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70725
Vancouver
Liu X, Li Z, Zhang C, Liang J, Zhou N. Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70725
BibTeX
@article{Liu2026,
author = {Liu, Xiaoyang and Li, Zizhang and Zhang, Chengguo and Liang, Jun and Zhou, Nan},
title = {Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.70725}
}
EUVIMED